Theurillat Group
Theurillat Group

We aim to explore the role of SPOP and CHD1 mutations to develop new therapeutic avenues for prostate cancer.

Alimonti group
Alimonti group

Our research is focused on the characterization of a novel type of cellular senescence response for cancer therapy

Catapano group
Catapano group

We investigate strategies aimed at blocking selectively transcription of genes that might be implicated in pathogenesis of cancer

Bertoni group
Bertoni group

We apply genomics techniques followed by functional studies to elucidate the lesions underlying non-Hodgkin’s lymphomas

Fighting cancer through research. You can support us by making a donation, however large or small.

Support us

Portrait

The Institute of Oncology Research (IOR), established in 2003 in Bellinzona, Switzerland, hosts researchers from all over the world performing basic and translational research in oncology with special focus on:

  • cancer biology
  • genomics
  • molecular oncology
  • experimental therapeutics.

At the Institute of Oncology Research we believe that science is constantly evolving to improve our understanding of human cancer.

The efforts of our researchers and the resources of the institute are directed towards this challenge, with a commitment to discovering practical and far-reaching solutions to a disease that still impacts on the everyday life of people around the world.

news

New publication by Giuseppina Carbone’s Prostate Cancer Biology group
15 Jan

New publication by Giuseppina Carbone’s Prostate Cancer Biology group

A new study, published in the journal Cancers describes a novel approach to dissect the intrinsic he...
Mitochondrial reprogramming heads stem cell expansion and castration-resistance in prostate cancer – New grant awarded to Prof. Carlo Catapano
23 Dec

Mitochondrial reprogramming heads stem cell expansion and castration-resistance in prostate cancer – New grant awarded to Prof. Carlo Catapano

New grant awarded by the Swiss Cancer League to the Tumor Biology and Experimental Therapeutics Grou...
Combinatorial nanomedicines for precision therapy of prostate cancer at the IOR – New grant awarded to Prof. Carlo Catapano
18 Dec

Combinatorial nanomedicines for precision therapy of prostate cancer at the IOR – New grant awarded to Prof. Carlo Catapano

New grant awarded to the Tumor Biology and Experimental Therapeutics Group headed by the IOR Directo...

Research

Jobs

Publications